Secondary Logo

Share this article on:

Pancreatic-Type Mixed Acinar Neuroendocrine Carcinoma Arising in the Common Bile Duct

A Case Report

Shafique, Khurram, MD*; Lee, Lik Hang, MD; Samad, Arbaz, MD; Wang, Lu, MD, PhD§; Klimstra, David S., MD§∥

doi: 10.1097/PCR.0000000000000278
Case Reports

Mixed acinar neuroendocrine carcinoma (MAcNEC) of pancreatic type arising in an extrapancreatic location is extremely rare. We present a case of a 70-year-old woman with constipation, abdominal discomfort, and jaundice. Imaging studies revealed a 1.8-cm solid mass in the common bile duct causing dilatation of intrahepatic and extrahepatic bile ducts, which was resected. Microscopically, the tumor was limited to the wall of the bile duct, without involvement of the pancreas, and was composed of solid sheets and nests of relatively monomorphic cells with minimal to moderate amounts of cytoplasm, granular chromatin, focally prominent nucleoli, and up to 160 mitoses per 10 high-power fields. Immunohistochemistry showed equal to or greater than 30% positivity for synaptophysin, chromogranin, chymotrypsin, and trypsin. A diagnosis of MAcNEC was rendered. Immunohistochemistry plays a pivotal role in the identification of these tumors and discrimination from other related entities, neuroendocrine neoplasms in particular. Because pancreatic heterotopia has been described in the common bile duct, we postulate that this case of MAcNEC in the common bile duct, the first to be reported in the literature, may have arisen via malignant transformation of pancreatic heterotopia.

From the *Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA;

Department of Pathology and Laboratory Medicine, University of British Columbia, St Paul's Hospital, Vancouver, British Columbia, Canada;

Department of Pathology, Atlantic Health System, Morristown, NJ;

§Department of Pathology, St Jude Children's Research Hospital, Memphis, TN; and

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Reprints: Khurram Shafique, MD, Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, 6 Founders, Room FO6.055, 3400 Spruce Street, Philadelphia, PA 19104. E-mail: Khurram.Shafique@uphs.upenn.edu.

The authors have no funding or conflicts to declare.

Pancreatic acinar cell carcinomas account for 1% to 2% of all exocrine pancreatic tumors.1,2 They are composed predominantly of acinar components but may contain a minor component of neuroendocrine cells identifiable by immunohistochemistry. Pancreatic neuroendocrine tumors are also uncommon, representing 2% of all pancreatic neoplasms. The term mixed acinar neuroendocrine carcinoma (MAcNEC) is used for pancreatic neoplasms with significant components (>25%–30%) of both elements.3 The individual neoplastic cells may also express both acinar and neuroendocrine phenotypes concurrently, and some authors have used the term “amphicrine” to describe these mixed carcinomas. Mixed acinar neuroendocrine carcinomas are extremely rare, with only few cases reported, mostly primary in the pancreas,3,4 with a handful of reported cases in extrapancreatic sites including the stomach and ampulla.5–7 Our case represents the first reported case of a MAcNEC arising in the extrapancreatic common bile duct.

Back to Top | Article Outline

CASE REPORT

We present the case of a 70-year-old woman with a history of smoking, recent right fibular spiral fracture, and restless leg syndrome who presented to emergency department with constipation followed by abdominal cramping, nausea, and jaundice for 3 weeks. She had pruritus, dark urine, and light-colored stools. Her laboratory test values showed an elevated total bilirubin of 20.5 mg/dL, as well as elevated liver enzymes (aspartate transaminase of 93 U/L, alanine transaminase of 144 U/L, and alkaline phosphatase of 373 IU/L). Serum marker CA-19-9 was elevated at 1337.9 U/mL, whereas CA-125, CA-27–29, and CA-15-3 were within normal limits.

A computed tomography scan of the abdomen and pelvis showed significant intrahepatic and extrahepatic ductal dilatation that was cut off at the porta hepatis by a mass in the common bile duct. It was not clear radiologically whether the mass was intraductal or extraductal. The mass was separate from the pancreas, which was unremarkable except for a 3-mm cyst in the body.

Clinically, a diagnosis of bile duct carcinoma was suspected. Fine-needle aspiration of the common bile duct mass was performed that was diagnosed as “positive for poorly differentiated carcinoma with neuroendocrine differentiation” due to synaptophysin and chromogranin positivity.

Laparotomy with segmental resection of common bile duct, cholecystectomy, portal lymphadenectomy, and choledochojejunostomy was performed. Pancreas was not resected. On gross examination, there was a 1.8 × 1.2 × 1-cm polypoid mass in the common bile duct obstructing the lumen. The mass focally infiltrated into the wall and abutted the proximal margin.

Microscopic examination showed a tumor immediately beneath the common bile duct epithelium that consisted of sheets and nodules of relatively monomorphic cells containing moderate amounts of cytoplasm with mild granularity (Fig. 1). There were areas with rosette-like formations. The nuclei were generally uniform with clumped chromatin. Nucleoli were conspicuous in some regions. One large nodule, in particular, was more solid and was composed of cells with less cytoplasm and increased nuclear atypia (Fig. 2). The mitotic rate ranged from 7 in 10 high-power fields in most regions, to 160 mitoses per 10 high-power fields in the more solid nodule. This variability in mitotic rate was also reflected in the Ki-67 index, with the less proliferative areas having a Ki-67 index of 19%, and the solid nodule having a Ki-67 index of 80%.

FIGURE 1

FIGURE 1

FIGURE 2

FIGURE 2

Immunohistochemistry showed that the tumor cells were positive for epithelial markers (OSCAR, CK8/18, CK7), with faint and patchy positivity for neuroendocrine markers (synaptophysin and chromogranin) and significant positivity (~30%) for acinar markers (trypsin and chymotrypsin) (Fig. 3). Based on the histomorphological and immunohistochemical profile, a diagnosis of MAcNEC of pancreatic type was rendered. Lymphovascular invasion was identified with 3 of 10 lymph nodes positive for metastatic carcinoma, with the metastases composed of the solid and more proliferative component.

FIGURE 3

FIGURE 3

A break-apart fluorescence in situ hybridization assay for BRAF fusions was negative for BRAF gene rearrangement. Loss of 1 copy of BRAF was seen in 50% of the cells analyzed.

Back to Top | Article Outline

DISCUSSION

The exocrine and neuroendocrine components of pancreas have a common embryological origin, which forms the basis of development of MAcNECs.2 The term “mixed acinar endocrine carcinoma” was first proposed by Klimstra et al2 in 1994 when they presented 5 cases of acinar cell carcinoma with at least 25% neuroendocrine elements. According to the World Health Organization (WHO), the diagnosis of MAcNEC is reserved for acinar neoplasms that have greater than 30% neuroendocrine cell type.3 The mean age of occurrence of these carcinomas is 60 years with a male-to-female ratio of 2:3.2 It is interesting to note that even though these neoplasms have significant numbers of neuroendocrine cells, they rarely express pancreatic or gastrointestinal hormones.8

The current case is of particular interest because of its unique location. Acinar cell neoplasia most often arises in the pancreas, but there are rare examples arising in extrapancreatic locations, particularly along the gastrointestinal tract (including at the ampulla of Vater,9 jejunum,10 and colon11 and most notably in the stomach12–15). These are thought to originate from heterotopic pancreatic tissue because their distribution correlates to locations where pancreatic heterotopia or metaplasia is frequently seen. Heterotopic pancreas has been reported in 0.5% to 13.7% of all autopsies16 and is most often found in the duodenum, stomach, jejunum, Meckel diverticulum, and ileum.5 However, this theory remains a speculation because residual nonneoplastic pancreatic heterotopic tissue is rarely actually identified. Interestingly, the liver is another common location for extrapancreatic acinar cell neoplasms.16–19 The histogenesis is also uncertain as ectopic pancreatic tissue is uncommon in the liver. Heterotopic pancreatic tissue is occasionally found adjacent to larger intrahepatic bile ducts, perhaps accounting for the rare cases of primary hepatic acinar cell carcinoma. Moreover, embryologic and immunomorphologic studies have provided evidence that pancreatic, hepatic, and biliary tract epithelium originates from the same progenitor cells.20–23 Furthermore, pancreatic acinar cell carcinomas have been reported to produce α-fetoprotein, similar to hepatocellular carcinomas. Therefore, these noncommitted progenitor cells may follow a pure acinar cell differentiation and be the origin of hepatic acinar cell neoplasms. Finally, extrapancreatic acinar cell neoplasms have also been reported originating from the somatic transformation of a teratomatous germ cell tumor.24,25

Mixed acinar neuroendocrine carcinomas arising in extrapancreatic locations are even rarer, with variants having been described only in isolated reports in the stomach and ampulla. Fukunaga et al26 described a well-differentiated adenocarcinoma with admixed acinar and endocrine components as demonstrated by immunohistochemistry. Three cases of composite glandular and endocrine tumors with pancreatic acinar differentiation arising in the stomach were reported by Jain et al.12 Kusafuka et al5 also reported a case of a MAcNEC arising in the stomach that was, interestingly, associated with an elevated α-fetoprotein level. Similar to other acinar cell neoplasms, MAcNECs arising in the stomach are assumed to arise from pancreatic heterotopia or acinar metaplasia, which is commonly seen in gastric mucosa.27 Two cases of MAcNECs were also described at the ampulla,6,7 with the case by Moncur et al6 described as originating in the duodenum.

Our current case is the first MAcNEC to be described arising in the common bile duct, away from the pancreas, stomach, and ampulla. The possible etiologies essentially reiterate the possible origins of any extrapancreatic acinar cell neoplasm as described above. Rare cases of pancreatic heterotopia have also been reported in the common bile duct.28 Also, origin in uncommitted progenitor cells remains a reasonable hypothesis. Reid22 and Carpino et al23 showed that multipotent biliary tree stem/progenitor cells are found at the bottom of peribiliary glands near the fibromuscular layer. These cells are phenotypically heterogeneous and express transcription factors as well as surface and cytoplasmic markers for progenitors of liver, pancreas, and endoderm. Since they have been shown to give rise, in vitro and in vivo, to hepatocytes, cholangiocytes, and the endocrine cells of pancreatic islets, they could be involved in the histogenesis of the MAcNEC in our case.22,23 Of course, a more distinct possibility is that of metastasis. The pancreas was not resected in this patient. However, no additional lesions in the pancreas or elsewhere have been identified in multiple imaging studies at the time of diagnosis and in follow-up.

Histologically, 3 patterns of MAcNECs have been described.2,4 The first pattern is composed of 2 distinct and separate populations of neoplastic cells that can be recognized by light microscopy (so-called “collision” pattern). The second pattern is composed of an intimate mixture of acinar and neuroendocrine cells that are morphologically difficult to distinguish. They often form a uniform and solid architecture and require the use of immunohistochemistry to identify the 2 cell populations. The third pattern is composed of a population of amphicrine cells that express both acinar and neuroendocrine features. This pattern is difficult to distinguish from the second pattern without performing dual-labeling immunohistochemistry to prove the amphicrine nature of the cells. The second pattern comprises the vast majority of MAcNECs.2 In comparison with pure acinic cell carcinomas, which may contain scattered neuroendocrine cells in 42% of cases, a major (albeit arbitrary) distinguishing feature of MAcNECs is the percentage of tumor cells positive for neuroendocrine markers.1,8 Tumors with a predominantly acinar cell morphology containing at least 25% to 30% neuroendocrine cells should be diagnosed as a MAcNEC.2–4 On cytological specimens, these tumors are particularly challenging to distinguish from pure acinar cell carcinoma, requiring careful use of immunohistochemistry for neuroendocrine and acinar markers for diagnosis.29 A minimum of 20% cells on cytological specimens expressing at least 1 neuroendocrine marker (synaptophysin or chromogranin) would suggest the diagnosis of a MAcNEC for a neoplasm with predominantly acinar differentiation.30

Most reported MAcNECs consist predominantly of acinar elements, and these neoplasms are believed to be biologically closely related to pure acinar cell carcinomas. Clinical and genetic features of these neoplasms overlap, to the extent that some authorities regard MAcNECs as simply variants of acinar cell carcinomas.4 Occasionally, however, the neuroendocrine component can predominate, but nonetheless, the behavior is more aggressive than that of a well-differentiated neuroendocrine tumor.4 Therefore, the distinction between MAcNECs and neuroendocrine tumors is important. Chemotherapy and radiotherapy may be transiently effective, if at all, for MAcNECs, and most patients die of disease, with a survival rate similar to that of pure acinar cell carcinomas (5-year survival, 35%).31,32 On the other hand, well-differentiated neuroendocrine tumors may be cured by surgical resection alone, and long-term survival occurs even in patients with incurable metastases. Morphologically, well-differentiated neuroendocrine tumors are composed of sheets, trabeculae, and cords of cells arranged in clusters or small nests separated by hyalinized or fibrotic stroma. Tumor cells have mild to moderate cytologic atypia with round nuclei, stippled chromatin, and inconspicuous nucleoli. They generally have a low mitotic rate (<20 mitoses per 10 high-power fields, and often <3). Unlike MAcNEC, well-differentiated neuroendocrine tumors do not have morphologically identifiable areas of acinar differentiation, but they may contain individual cells expressing acinar differentiation by immunohistochemistry, again arguing that a significant proportion of cells (25%–30%) expressing acinar differentiation must be present for the diagnosis of MAcNEC to be made.33,34

The identification of MAcNECs is not always obvious. This is particularly true for tumors with the second or third patterns of MAcNECs as described above because of the homogenous appearance of the cell population. In the current case, prior to immunohistochemical staining, the morphologic diagnosis was favored to be a WHO grade 2 well-differentiated neuroendocrine tumor, with the more proliferative solid nodule representing transformation to a high-grade (WHO G3) component, a phenomenon now well described in primary pancreatic neuroendocrine neoplasms and also in a few extrapancreatic primaries.35 Acinar differentiation was not initially suspected, particularly because of the origin of the tumor in the common bile duct, where neuroendocrine but not acinar neoplasms are recognized to arise. Clues to acinar differentiation that were present included an elevated mitotic rate (and Ki-67 index), focally prominent nucleoli, and mild granularity to the cytoplasm. The difficulty of distinguishing pancreatic acinar neoplasms from neuroendocrine tumors has been repeatedly acknowledged, arguing for immunolabeling for both neuroendocrine (synaptophysin and chromogranin) and acinar (trypsin, chymotrypsin, and bcl10) markers in all but the most histologically classic cases.36

Recently, genomic profiling of pancreatic acinar cell carcinoma, including mixed variants, has led to the discovery of recurrent fusions in BRAF and RAF1 (seen in 23% of cases).37,38 Chmielecki et al38 found that acinar cell carcinomas with a specific recurrent BRAF fusion, SND1-BRAF, had activation of the MAPK pathway, potentially conferring sensitivity to treatment with MEK inhibitors such as trametinib. They also found that “fusion-negative” tumors showed genomic alterations that led to inactivation of DNA repair genes (45% of cases). These tumors may be more sensitive to platinum-based chemotherapy and PARP inhibitors.38 The identification of actionable genomic alterations is a step toward the personalized targeted therapy in pure and mixed acinar cell carcinomas. In the current case, BRAF fusions were not identified using a recently developed break-apart fluorescence in situ hybridization assay.39 While the significance of the BRAF copy number loss detected in the current case is unknown, it would not be predicted to cause activation of the MAPK pathway, and therefore MEK inhibition would not be a rational therapeutic strategy.

Back to Top | Article Outline

CONCLUSIONS

MAcNECs are rare carcinomas that are mostly found arising from the pancreas and have rarely been reported in the stomach and ampulla. We have described the first reported case of a MAcNEC arising in the common bile duct.

Back to Top | Article Outline

REFERENCES

1. Klimstra DS, Heffess CS, Oertel JE, et al. Acinar cell carcinoma of the pancreas. A clinicopathologic study of 28 cases. Am J Surg Pathol 1992;16(9):815–837.
2. Klimstra DS, Rosai J, Heffess CS. Mixed acinar-endocrine carcinomas of the pancreas. Am J Surg Pathol 1994;18(8):765–778.
3. Bosman FT; World Health Organization International Agency for Research on Cancer. WHO Classification of Tumours of the Digestive System. 4th ed. Lyon, France: International Agency for Research on Cancer; 2010.
4. Jakobsen M, Klöppel G, Detlefsen S. Mixed acinar-neuroendocrine carcinoma of the pancreas: a case report and a review. Histol Histopathol 2016;31:1381–1388.
5. Kusafuka K, Bando E, Muramatsu K, et al. Pancreatic-type mixed acinar-endocrine carcinoma with alpha-fetoprotein production arising from the stomach: a report of an extremely rare case. Med Mol Morphol 2009;42(3):167–174.
6. Moncur JT, Lacy BE, Longnecker DS. Mixed acinar-endocrine carcinoma arising in the ampulla of Vater. Hum Pathol 2002;33(4):449–451.
7. Soubra A, Faraj W, Saab J, et al. Peri-ampullary mixed acinar-endocrine carcinoma. Rare Tumors 2011;3(2):e15.
8. Ohike N, Kosmahl M, Klöppel G. Mixed acinar-endocrine carcinoma of the pancreas. A clinicopathological study and comparison with acinar-cell carcinoma. Virchows Arch 2004;445(3):231–235.
9. Kawakami H, Kuwatani M, Onodera M, et al. Primary acinar cell carcinoma of the ampulla of Vater. J Gastroenterol 2007;42(8):694–697.
10. Makhlouf HR, Almeida JL, Sobin LH. Carcinoma in jejunal pancreatic heterotopia. Arch Pathol Lab Med 1999;123(8):707–711.
11. Chiaravalli AM, Finzi G, Bertolini V, et al. Colonic carcinoma with a pancreatic acinar cell differentiation. A case report. Virchows Arch 2009;455(6):527–531.
12. Jain D, Eslami-Varzaneh F, Takano AM, et al. Composite glandular and endocrine tumors of the stomach with pancreatic acinar differentiation. Am J Surg Pathol 2005;29(11):1524–1529.
13. Sun Y, Wasserman PG. Acinar cell carcinoma arising in the stomach: a case report with literature review. Hum Pathol 2004;35(2):263–265.
14. Mizuno Y, Sumi Y, Nachi S, et al. Acinar cell carcinoma arising from an ectopic pancreas. Surg Today 2007;37(8):704–707.
15. Ambrosini-Spaltro A, Poti O, De Palma M, et al. Pancreatic-type acinar cell carcinoma of the stomach beneath a focus of pancreatic metaplasia of the gastric mucosa. Hum Pathol 2009;40(5):746–749.
16. Agaimy A, Kaiser A, Becker K, et al. Pancreatic-type acinar cell carcinoma of the liver: a clinicopathologic study of four patients. Mod Pathol 2011;24(12):1620–1626.
17. Wildgruber M, Rummeny EJ, Gaa J. Primary acinar cell carcinoma of the liver. Rofo 2013;185(6):572–573.
18. Zundler S, Erber R, Agaimy A, et al. Pancreatic panniculitis in a patient with pancreatic-type acinar cell carcinoma of the liver—case report and review of literature. BMC Cancer 2016;16:130.
19. Hervieu V, Lombard-Bohas C, Dumortier J, et al. Primary acinar cell carcinoma of the liver. Virchows Arch 2008;452(3):337–341.
20. Deutsch G, Jung J, Zheng M, et al. A bipotential precursor population for pancreas and liver within the embryonic endoderm. Development 2001;128(6):871–881.
21. Kuo FY, Swanson PE, Yeh MM. Pancreatic acinar tissue in liver explants: a morphologic and immunohistochemical study. Am J Surg Pathol 2009;33(1):66–71.
22. Reid LM. Stem/progenitor cells and reprogramming (plasticity) mechanisms in liver, biliary tree, and pancreas. Hepatology 2016;64(1):4–7.
23. Carpino G, Cardinale V, Onori P, et al. Biliary tree stem/progenitor cells in glands of extrahepatic and intraheptic bile ducts: an anatomical in situ study yielding evidence of maturational lineages. J Anat 2012;220(2):186–199.
24. Cingolani N, Shaco-Levy R, Farruggio A, et al. Alpha-fetoprotein production by pancreatic tumors exhibiting acinar cell differentiation: study of five cases, one arising in a mediastinal teratoma. Hum Pathol 2000;31(8):938–944.
25. Suda K, Mizuguchi K, Hebisawa A, et al. Pancreatic tissue in teratoma. Arch Pathol Lab Med 1984;108(10):835–837.
26. Fukunaga M. Gastric carcinoma resembling pancreatic mixed acinar-endocrine carcinoma. Hum Pathol 2002;33(5):569–573.
27. Doglioni C, Laurino L, Dei Tos AP, et al. Pancreatic (acinar) metaplasia of the gastric mucosa. Histology, ultrastructure, immunocytochemistry, and clinicopathologic correlations of 101 cases. Am J Surg Pathol 1993;17(11):1134–1143.
28. Sumiyoshi T, Shima Y, Okabayashi T, et al. Heterotopic pancreas in the common bile duct, with a review of the literature. Intern Med 2014;53(23):2679–2682.
29. Sullivan PS, Clebanoff JL, Hirschowitz SL. Hints to the diagnosis of mixed acinar-endocrine carcinoma on pancreatic fine-needle aspiration: avoiding a potential diagnostic pitfall. Acta Cytol 2013;57(3):296–302.
30. Sigel CS, Klimstra DS. Cytomorphologic and immunophenotypical features of acinar cell neoplasms of the pancreas. Cancer Cytopathol 2013;121(8):459–470.
31. Holen KD, Klimstra DS, Hummer A, et al. Clinical characteristics and outcomes from an institutional series of acinar cell carcinoma of the pancreas and related tumors. J Clin Oncol 2002;20(24):4673–4678.
32. La Rosa S, Adsay V, Albarello L, et al. Clinicopathologic study of 62 acinar cell carcinomas of the pancreas: insights into the morphology and immunophenotype and search for prognostic markers. Am J Surg Pathol 2012;36(12):1782–1795.
33. Yantiss RK, Chang HK, Farraye FA, et al. Prevalence and prognostic significance of acinar cell differentiation in pancreatic endocrine tumors. Am J Surg Pathol 2002;26(7):893–901.
34. Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20(11):2633–2642.
35. Basturk O, Yang Z, Tang LH, et al. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 2015;39(5):683–690.
36. Hosoda W, Sasaki E, Murakami Y, et al. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. Pathol Int 2013;63(3):176–182.
37. Jiao Y, Yonescu R, Offerhaus GJ, et al. Whole-exome sequencing of pancreatic neoplasms with acinar differentiation. J Pathol 2014;232(4):428–435.
38. Chmielecki J, Hutchinson KE, Frampton GM, et al. Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes. Cancer Discov 2014;4(12):1398–1405.
39. Ho C, Mullaney K, OReilly C, Jour G, et al. Detection of sarcoma oncogenic fusion transcripts using Archer(TM) sequencing technology. Mod Pathol 2016;29(Suppl. 2).
Keywords:

common bile duct cancer; mixed acinar neuroendocrine carcinoma; pancreatic cancer; pancreatic heterotopia

© 2018 Lippincott Williams & Wilkins, Inc.